NTLA Q3 2018 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+1.2% YoY

Gross Profit

-$16M-213.7% margin

Operating Income

-$24M-325.3% margin

Net Income

-$23M-306.5% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$321M

Total Liabilities

$58M

Stockholders' Equity

$263M

Cash & Equivalents

$293M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	+1.2%
Gross Profit	-$16M	-$10M	-55.7%
Operating Income	-$24M	-$16M	-51.8%
Net Income	-$23M	-$15M	-47.8%